Adagrasib (Krazati) Approved for KRAS-Mutated NSCLC

It becomes the second KRAS-targeted therapy for use in patients with non–small cell lung cancer (NSCLC) whose tumors have this mutation.
FDA Approvals

source https://www.medscape.com/viewarticle/985480?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?